Dermira data could bolster bid as Dupixent alternative

Dermira added $80 million to its market cap Friday on detailed Phase IIb data that lend additional support to the idea that its atopic dermatitis therapy could compete with Dupixent on dosing.

Dermira Inc. (NASDAQ:DERM) reported top-line data

Read the full 379 word article

User Sign In